Selected research
Industry Research
Musculoskeletal System Disorder Drug Industry Research Report 2026
Market perspective
The global Musculoskeletal System Disorder Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Musculoskeletal System Disorder Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Musculoskeletal System Disorder Drug market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Musculoskeletal System Disorder Drug market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Musculoskeletal System Disorder Drug include Sanofi, Johnson & Johnson, Novartis, Eli Lilly, Pfizer, AbbVie, Torrent Pharmaceuticals, Nippon Shinyaku and Merck & Co, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Musculoskeletal System Disorder Drug market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Musculoskeletal System Disorder Drug.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Musculoskeletal System Disorder Drug Market by Company
Sanofi
Johnson & Johnson
Novartis
Eli Lilly
Pfizer
AbbVie
Torrent Pharmaceuticals
Nippon Shinyaku
Merck & Co
GSK
Eisai
Cadila Healthcare
Bayer
Astellas Pharma
Asahi Kasei
Amgen
Abbott
Musculoskeletal System Disorder Drug Segment by Type
Bone Disorder
Joint Disorder
Muscle Disorder
Other
Musculoskeletal System Disorder Drug Segment by Application
Hospital & Clinic
Retail Pharmacy
Other
Musculoskeletal System Disorder Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Musculoskeletal System Disorder Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Musculoskeletal System Disorder Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Musculoskeletal System Disorder Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Musculoskeletal System Disorder Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Bone Disorder
- Joint Disorder
- Muscle Disorder
- Other
Applications
- Hospital & Clinic
- Retail Pharmacy
- Other
Companies covered
- Sanofi
- Johnson & Johnson
- Novartis
- Eli Lilly
- Pfizer
- AbbVie
- Torrent Pharmaceuticals
- Nippon Shinyaku
- Merck & Co
- GSK
- Eisai
- Cadila Healthcare
- Bayer
- Astellas Pharma
- Asahi Kasei
- Amgen
- Abbott
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Musculoskeletal System Disorder Drug by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Bone Disorder
- 2.2.3 Joint Disorder
- 2.2.4 Muscle Disorder
- 2.2.5 Other
- 2.3 Musculoskeletal System Disorder Drug by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital & Clinic
- 2.3.3 Retail Pharmacy
- 2.3.4 Other
- 2.4 Assumptions and Limitations
3 Musculoskeletal System Disorder Drug Breakdown Data by Type
- 3.1 Global Musculoskeletal System Disorder Drug Historic Market Size by Type (2021-2026)
- 3.2 Global Musculoskeletal System Disorder Drug Forecasted Market Size by Type (2027-2032)
4 Musculoskeletal System Disorder Drug Breakdown Data by Application
- 4.1 Global Musculoskeletal System Disorder Drug Historic Market Size by Application (2021-2026)
- 4.2 Global Musculoskeletal System Disorder Drug Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Musculoskeletal System Disorder Drug Market Perspective (2021-2032)
- 5.2 Global Musculoskeletal System Disorder Drug Growth Trends by Region
- 5.2.1 Global Musculoskeletal System Disorder Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Musculoskeletal System Disorder Drug Historic Market Size by Region (2021-2026)
- 5.2.3 Musculoskeletal System Disorder Drug Forecasted Market Size by Region (2027-2032)
- 5.3 Musculoskeletal System Disorder Drug Market Dynamics
- 5.3.1 Musculoskeletal System Disorder Drug Industry Trends
- 5.3.2 Musculoskeletal System Disorder Drug Market Drivers
- 5.3.3 Musculoskeletal System Disorder Drug Market Challenges
- 5.3.4 Musculoskeletal System Disorder Drug Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Musculoskeletal System Disorder Drug Players by Revenue
- 6.1.1 Global Top Musculoskeletal System Disorder Drug Players by Revenue (2021-2026)
- 6.1.2 Global Musculoskeletal System Disorder Drug Revenue Market Share by Players (2021-2026)
- 6.2 Global Musculoskeletal System Disorder Drug Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Musculoskeletal System Disorder Drug Head Office and Area Served
- 6.4 Global Musculoskeletal System Disorder Drug Players, Product Type & Application
- 6.5 Global Musculoskeletal System Disorder Drug Manufacturers Established Date
- 6.6 Global Musculoskeletal System Disorder Drug Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Musculoskeletal System Disorder Drug Market Size (2021-2032)
- 7.2 North America Musculoskeletal System Disorder Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Musculoskeletal System Disorder Drug Market Size by Country (2021-2026)
- 7.4 North America Musculoskeletal System Disorder Drug Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Musculoskeletal System Disorder Drug Market Size (2021-2032)
- 8.2 Europe Musculoskeletal System Disorder Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Musculoskeletal System Disorder Drug Market Size by Country (2021-2026)
- 8.4 Europe Musculoskeletal System Disorder Drug Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Musculoskeletal System Disorder Drug Market Size (2021-2032)
- 9.2 Asia-Pacific Musculoskeletal System Disorder Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Musculoskeletal System Disorder Drug Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Musculoskeletal System Disorder Drug Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Musculoskeletal System Disorder Drug Market Size (2021-2032)
- 10.2 South America Musculoskeletal System Disorder Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Musculoskeletal System Disorder Drug Market Size by Country (2021-2026)
- 10.4 South America Musculoskeletal System Disorder Drug Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Musculoskeletal System Disorder Drug Market Size (2021-2032)
- 11.2 Middle East & Africa Musculoskeletal System Disorder Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Musculoskeletal System Disorder Drug Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Musculoskeletal System Disorder Drug Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Sanofi
- 12.1.1 Sanofi Company Information
- 12.1.2 Sanofi Business Overview
- 12.1.3 Sanofi Revenue in Musculoskeletal System Disorder Drug Business (2021-2026)
- 12.1.4 Sanofi Musculoskeletal System Disorder Drug Product Portfolio
- 12.1.5 Sanofi Recent Developments
- 12.2 Johnson & Johnson
- 12.2.1 Johnson & Johnson Company Information
- 12.2.2 Johnson & Johnson Business Overview
- 12.2.3 Johnson & Johnson Revenue in Musculoskeletal System Disorder Drug Business (2021-2026)
- 12.2.4 Johnson & Johnson Musculoskeletal System Disorder Drug Product Portfolio
- 12.2.5 Johnson & Johnson Recent Developments
- 12.3 Novartis
- 12.3.1 Novartis Company Information
- 12.3.2 Novartis Business Overview
- 12.3.3 Novartis Revenue in Musculoskeletal System Disorder Drug Business (2021-2026)
- 12.3.4 Novartis Musculoskeletal System Disorder Drug Product Portfolio
- 12.3.5 Novartis Recent Developments
- 12.4 Eli Lilly
- 12.4.1 Eli Lilly Company Information
- 12.4.2 Eli Lilly Business Overview
- 12.4.3 Eli Lilly Revenue in Musculoskeletal System Disorder Drug Business (2021-2026)
- 12.4.4 Eli Lilly Musculoskeletal System Disorder Drug Product Portfolio
- 12.4.5 Eli Lilly Recent Developments
- 12.5 Pfizer
- 12.5.1 Pfizer Company Information
- 12.5.2 Pfizer Business Overview
- 12.5.3 Pfizer Revenue in Musculoskeletal System Disorder Drug Business (2021-2026)
- 12.5.4 Pfizer Musculoskeletal System Disorder Drug Product Portfolio
- 12.5.5 Pfizer Recent Developments
- 12.6 AbbVie
- 12.6.1 AbbVie Company Information
- 12.6.2 AbbVie Business Overview
- 12.6.3 AbbVie Revenue in Musculoskeletal System Disorder Drug Business (2021-2026)
- 12.6.4 AbbVie Musculoskeletal System Disorder Drug Product Portfolio
- 12.6.5 AbbVie Recent Developments
- 12.7 Torrent Pharmaceuticals
- 12.7.1 Torrent Pharmaceuticals Company Information
- 12.7.2 Torrent Pharmaceuticals Business Overview
- 12.7.3 Torrent Pharmaceuticals Revenue in Musculoskeletal System Disorder Drug Business (2021-2026)
- 12.7.4 Torrent Pharmaceuticals Musculoskeletal System Disorder Drug Product Portfolio
- 12.7.5 Torrent Pharmaceuticals Recent Developments
- 12.8 Nippon Shinyaku
- 12.8.1 Nippon Shinyaku Company Information
- 12.8.2 Nippon Shinyaku Business Overview
- 12.8.3 Nippon Shinyaku Revenue in Musculoskeletal System Disorder Drug Business (2021-2026)
- 12.8.4 Nippon Shinyaku Musculoskeletal System Disorder Drug Product Portfolio
- 12.8.5 Nippon Shinyaku Recent Developments
- 12.9 Merck & Co
- 12.9.1 Merck & Co Company Information
- 12.9.2 Merck & Co Business Overview
- 12.9.3 Merck & Co Revenue in Musculoskeletal System Disorder Drug Business (2021-2026)
- 12.9.4 Merck & Co Musculoskeletal System Disorder Drug Product Portfolio
- 12.9.5 Merck & Co Recent Developments
- 12.10 GSK
- 12.10.1 GSK Company Information
- 12.10.2 GSK Business Overview
- 12.10.3 GSK Revenue in Musculoskeletal System Disorder Drug Business (2021-2026)
- 12.10.4 GSK Musculoskeletal System Disorder Drug Product Portfolio
- 12.10.5 GSK Recent Developments
- 12.11 Eisai
- 12.11.1 Eisai Company Information
- 12.11.2 Eisai Business Overview
- 12.11.3 Eisai Revenue in Musculoskeletal System Disorder Drug Business (2021-2026)
- 12.11.4 Eisai Musculoskeletal System Disorder Drug Product Portfolio
- 12.11.5 Eisai Recent Developments
- 12.12 Cadila Healthcare
- 12.12.1 Cadila Healthcare Company Information
- 12.12.2 Cadila Healthcare Business Overview
- 12.12.3 Cadila Healthcare Revenue in Musculoskeletal System Disorder Drug Business (2021-2026)
- 12.12.4 Cadila Healthcare Musculoskeletal System Disorder Drug Product Portfolio
- 12.12.5 Cadila Healthcare Recent Developments
- 12.13 Bayer
- 12.13.1 Bayer Company Information
- 12.13.2 Bayer Business Overview
- 12.13.3 Bayer Revenue in Musculoskeletal System Disorder Drug Business (2021-2026)
- 12.13.4 Bayer Musculoskeletal System Disorder Drug Product Portfolio
- 12.13.5 Bayer Recent Developments
- 12.14 Astellas Pharma
- 12.14.1 Astellas Pharma Company Information
- 12.14.2 Astellas Pharma Business Overview
- 12.14.3 Astellas Pharma Revenue in Musculoskeletal System Disorder Drug Business (2021-2026)
- 12.14.4 Astellas Pharma Musculoskeletal System Disorder Drug Product Portfolio
- 12.14.5 Astellas Pharma Recent Developments
- 12.15 Asahi Kasei
- 12.15.1 Asahi Kasei Company Information
- 12.15.2 Asahi Kasei Business Overview
- 12.15.3 Asahi Kasei Revenue in Musculoskeletal System Disorder Drug Business (2021-2026)
- 12.15.4 Asahi Kasei Musculoskeletal System Disorder Drug Product Portfolio
- 12.15.5 Asahi Kasei Recent Developments
- 12.16 Amgen
- 12.16.1 Amgen Company Information
- 12.16.2 Amgen Business Overview
- 12.16.3 Amgen Revenue in Musculoskeletal System Disorder Drug Business (2021-2026)
- 12.16.4 Amgen Musculoskeletal System Disorder Drug Product Portfolio
- 12.16.5 Amgen Recent Developments
- 12.17 Abbott
- 12.17.1 Abbott Company Information
- 12.17.2 Abbott Business Overview
- 12.17.3 Abbott Revenue in Musculoskeletal System Disorder Drug Business (2021-2026)
- 12.17.4 Abbott Musculoskeletal System Disorder Drug Product Portfolio
- 12.17.5 Abbott Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst